{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:56:02Z","timestamp":1792324562722,"version":"4.4.0"},"reference-count":63,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T00:00:00Z","timestamp":1494460800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G1002586"],"award-info":[{"award-number":["G1002586"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A high-throughput screen (HTS) was undertaken against the respiratory chain dehydrogenase component, NADH:menaquinone oxidoreductase (Ndh) of Mycobacterium tuberculosis (Mtb). The 11000 compounds were selected for the HTS based on the known phenothiazine Ndh inhibitors, trifluoperazine and thioridazine. Combined HTS (11000 compounds) and in-house screening of a limited number of quinolones (50 compounds) identified \u223c100 hits and four distinct chemotypes, the most promising of which contained the quinolone core. Subsequent Mtb screening of the complete in-house quinolone library (350 compounds) identified a further \u223c90 hits across three quinolone subtemplates. Quinolones containing the amine-based side chain were selected as the pharmacophore for further modification, resulting in metabolically stable quinolones effective against multi drug resistant (MDR) Mtb. The lead compound, 42a (MTC420), displays acceptable antituberculosis activity (Mtb IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM) and favorable pharmacokinetic and toxicological profiles.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6b01718","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T10:23:27Z","timestamp":1489746207000},"page":"3703-3726","source":"Crossref","is-referenced-by-count":54,"title":["Rational Design,\nSynthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting\nthe Respiratory Chain of\n                    <i>Mycobacterium tuberculosis<\/i>"],"prefix":"10.1021","volume":"60","author":[{"given":"W. David","family":"Hong","sequence":"first","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L69 7ZD"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Gibbons","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L69 7ZD"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suet C.","family":"Leung","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L69 7ZD"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Amewu","sequence":"additional","affiliation":[{"name":"University of Ghana , , P.O. Box LG56, ,","place":["Legon-Accra, Ghana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Stocks","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L69 7ZD"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Stachulski","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L69 7ZD"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Horta","sequence":"additional","affiliation":[{"name":"University of Algarve , , ,","place":["Faro, Portugal, 8005-139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L. S.","family":"Cristiano","sequence":"additional","affiliation":[{"name":"University of Algarve , , ,","place":["Faro, Portugal, 8005-139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison E.","family":"Shone","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , , Pembroke Place , ,","place":["Liverpool, U.K., L3 5QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Moss","sequence":"additional","affiliation":[{"name":"Keele University , , ,","place":["Keele, U.K., ST5 5BG"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Ardrey","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , , Pembroke Place , ,","place":["Liverpool, U.K., L3 5QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Sharma","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , , Pembroke Place , ,","place":["Liverpool, U.K., L3 5QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley J.","family":"Warman","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , , Pembroke Place , ,","place":["Liverpool, U.K., L3 5QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T. P.","family":"Bedingfield","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , , Pembroke Place , ,","place":["Liverpool, U.K., L3 5QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas E.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , , Pembroke Place , ,","place":["Liverpool, U.K., L3 5QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghaith","family":"Aljayyoussi","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , , Pembroke Place , ,","place":["Liverpool, U.K., L3 5QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Mead","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , , Pembroke Place , ,","place":["Liverpool, U.K., L3 5QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Caws","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , , Pembroke Place , ,","place":["Liverpool, U.K., L3 5QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil G.","family":"Berry","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L69 7ZD"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Ward","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , , Pembroke Place , ,","place":["Liverpool, U.K., L3 5QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo A.","family":"Biagini","sequence":"additional","affiliation":[{"name":"Liverpool School of Tropical Medicine , , Pembroke Place , ,","place":["Liverpool, U.K., L3 5QA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L69 7ZD"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9730-0960","authenticated-orcid":true,"given":"Gemma L.","family":"Nixon","sequence":"additional","affiliation":[{"name":"University of Liverpool , , ,","place":["Liverpool, U.K., L69 7ZD"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"2026090218203094600_cit1","unstructured":"Global Tuberculosis Report\n2015: Executive Summary, 20th ed.; World Health Organisation: Geneva,\nSwitzerland, 2015; pp 1\u20134."},{"key":"2026090218203094600_cit2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.meegid.2011.07.019","article-title":"Emergence\nand treatment of multidrug resistant (MDR) and extensively drug-resistant\n(XDR) tuberculosis in South Africa","volume":"12","author":"Streicher","year":"2012","journal-title":"Infect.,\nGenet. Evol."},{"key":"2026090218203094600_cit3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature09657","article-title":"The challenge of new\ndrug discovery for tuberculosis","volume":"469","author":"Koul","year":"2011","journal-title":"Nature"},{"key":"2026090218203094600_cit4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/0976-500X.124435","article-title":"Bedaquiline: A novel drug to combat\nmultiple drug-resistant tuberculosis","volume":"5","author":"Goel","year":"2014","journal-title":"J. Pharmacol.\nPharmacother."},{"key":"2026090218203094600_cit5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.4155\/fmc.11.79","article-title":"Diarylquinolines,\nsynthesis pathways and quantitative structure\u2013activity relationship\nstudies leading to the discovery of TMC207","volume":"3","author":"Guillemont","year":"2011","journal-title":"Future Med. Chem."},{"key":"2026090218203094600_cit6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4103\/0976-500X.136121","article-title":"Delamanid: A new armor in combating drug-resistant\ntuberculosis","volume":"5","author":"Xavier","year":"2014","journal-title":"J. Pharmacol. Pharmacother."},{"key":"2026090218203094600_cit7","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole\nderivative with promising action against tuberculosis in vitro and\nin mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med."},{"key":"2026090218203094600_cit8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40121-013-0009-3","article-title":"A Review of the evidence for using\nbedaquiline (TMC207) to treat multi-drug resistant tuberculosis","volume":"2","author":"Fox","year":"2013","journal-title":"Infect. Dis. Ther."},{"key":"2026090218203094600_cit9","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1073\/pnas.0500469102","article-title":"Inhibitors of type II NADH:menaquinone\noxidoreductase represent a class of antitubercular drugs","volume":"102","author":"Weinstein","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090218203094600_cit10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nchembio884","article-title":"Diarylquinolines target subunit c\nof mycobacterial ATP synthase","volume":"3","author":"Koul","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"2026090218203094600_cit11","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1128\/AAC.01393-08","article-title":"Selectivity of TMC207 towards mycobacterial ATP synthase compared\nwith that towards the eukaryotic homologue","volume":"53","author":"Haagsma","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090218203094600_cit12","doi-asserted-by":"publisher","first-page":"25273","DOI":"10.1074\/jbc.M803899200","article-title":"Diarylquinolines\nare bactericidal for dormant mycobacteria as a result of disturbed\nATP homeostasis","volume":"283","author":"Koul","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2026090218203094600_cit13","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline\nTMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2026090218203094600_cit14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/jac\/dks483","article-title":"Antitubercular pharmacodynamics\nof phenothiazines","volume":"68","author":"Warman","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090218203094600_cit15","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery\nof Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat. Med."},{"key":"2026090218203094600_cit16","doi-asserted-by":"publisher","first-page":"e52951","DOI":"10.1371\/journal.pone.0052951","article-title":"Identification\nof novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis\nQcrB","volume":"7","author":"Abrahams","year":"2012","journal-title":"PLoS One"},{"key":"2026090218203094600_cit17","first-page":"35","article-title":"Electron transport and respiration","volume-title":"Mycobacterium: Genomics and Molecular Biology","author":"Kana","year":"2009"},{"key":"2026090218203094600_cit18","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1073\/pnas.0711697105","article-title":"The protonmotive force is required for maintaining ATP homeostasis\nand viability of hypoxic, nonreplicating Mycobacterium tuberculosis","volume":"105","author":"Rao","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090218203094600_cit19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1574-6968.1995.tb07852.x","article-title":"Vigor, vitality\nand viability of microorganisms","volume":"133","author":"Lloyd","year":"1995","journal-title":"FEMS Microbiol.\nLett."},{"key":"2026090218203094600_cit20","doi-asserted-by":"publisher","first-page":"e1002251","DOI":"10.1371\/journal.ppat.1002251","article-title":"High-resolution phenotypic profiling defines genes\nessential for Mycobacterial growth and cholesterol catabolism","volume":"7","author":"Griffin","year":"2011","journal-title":"PLoS Pathog."},{"key":"2026090218203094600_cit21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.gene.2014.08.024","article-title":"Roles of the\ntwo type II NADH dehydrogenases in the survival of Mycobacterium tuberculosis\nin vitro","volume":"550","author":"Awasthy","year":"2014","journal-title":"Gene"},{"key":"2026090218203094600_cit22","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1046\/j.1365-2958.2002.02779.x","article-title":"Evaluation of a nutrient starvation\nmodel of Mycobacterium tuberculosis persistence by gene and protein\nexpression profiling","volume":"43","author":"Betts","year":"2002","journal-title":"Mol. Microbiol."},{"key":"2026090218203094600_cit23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1099\/00221287-63-1-41","article-title":"Inhibition by isoniazid\nof synthesis of mycolic acids in Mycobacterium tuberculosis","volume":"63","author":"Winder","year":"1970","journal-title":"J. Gen. Microbiol."},{"key":"2026090218203094600_cit24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2174\/156802607780059763","article-title":"The cell-wall core of mycobacterium\ntuberculosis in the context of drug discovery","volume":"7","author":"Brennan","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"2026090218203094600_cit25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/187152607781001763","article-title":"Mycobacterium tuberculosis DNA Gyrase\nas a target for drug discovery","volume":"7","author":"Mdluli","year":"2007","journal-title":"Infect. Disord.:\nDrug Targets"},{"key":"2026090218203094600_cit26","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1128\/AAC.48.4.1281-1288.2004","article-title":"Mycobacterium\ntuberculosis DNA Gyrase: Interaction with quinolones and correlation\nwith antimycobacterial drug activity","volume":"48","author":"Aubry","year":"2004","journal-title":"Antimicrob.\nAgents Chemother."},{"key":"2026090218203094600_cit27","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.1208813","article-title":"Pyrazinamide inhibits trans-translation\nin Mycobacterium tuberculosis","volume":"333","author":"Shi","year":"2011","journal-title":"Science"},{"key":"2026090218203094600_cit28","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural\nmechanism for rifampicin inhibition of bacterial RNA polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"2026090218203094600_cit29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0076-6879(08)04417-0","article-title":"Chapter 17 Type\nII NADH: quinone oxidoreductases of Plasmodium falciparum and Mycobacterium\ntuberculosis kinetic and high-throughput assays","volume":"456","author":"Fisher","year":"2009","journal-title":"Methods Enzymol."},{"key":"2026090218203094600_cit30","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/jac\/dks483","article-title":"Antitubercular\npharmacodynamics of phenothiazines","volume":"68","author":"Warman","year":"2013","journal-title":"J. Antimicrob.\nChemother."},{"key":"2026090218203094600_cit31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2436\/20.1501.01.229","article-title":"Phenothiazines as a solution for multidrug resistant\ntuberculosis: From the origin to present","volume":"18","author":"Kristiansen","year":"2015","journal-title":"Int.\nMicrobiol."},{"key":"2026090218203094600_cit32","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1021\/ci010132r","article-title":"Reoptimization of\nMDL keys for use in drug discovery","volume":"42","author":"Durant","year":"2002","journal-title":"J. Chem.\nInf. Comput. Sci."},{"key":"2026090218203094600_cit33","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.drudis.2006.10.005","article-title":"Similarity-based\nvirtual screening using 2D fingerprints","volume":"11","author":"Willett","year":"2006","journal-title":"Drug\nDiscovery Today"},{"key":"2026090218203094600_cit34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1021\/ci900419k","article-title":"Current trends in ligand-based\nvirtual screening: molecular representations, data mining methods,\nnew application areas, and performance evaluation","volume":"50","author":"Geppert","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"2026090218203094600_cit35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1021\/ci049847v","article-title":"PowerMV: a software environment for\nmolecular viewing, descriptor generation, data analysis and hit evaluation","volume":"45","author":"Liu","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"2026090218203094600_cit36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like\nproperties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2026090218203094600_cit37","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties\nthat influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"2026090218203094600_cit38","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1021\/jm701122q","article-title":"Generation\nof a set of simple, interpretable ADMET rules of thumb","volume":"51","author":"Gleeson","year":"2008","journal-title":"J. Med. Chem."},{"key":"2026090218203094600_cit39","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1016\/j.bmcl.2008.07.071","article-title":"Physiochemical\ndrug properties associated with in vivo toxicological outcomes","volume":"18","author":"Hughes","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090218203094600_cit40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1517\/17460441003605098","article-title":"Lipophilicity in drug discovery","volume":"5","author":"Waring","year":"2010","journal-title":"Expert Opin. Drug Discovery"},{"key":"2026090218203094600_cit41","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1021\/jm201179h","article-title":"Identification,\ndesign and biological evaluation of bisaryl quinolones targeting Plasmodium\nfalciparum Type II NADH:quinone oxidoreductase (PfNDH2)","volume":"55","author":"Pidathala","year":"2012","journal-title":"J. Med. Chem."},{"key":"2026090218203094600_cit42","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1021\/jm201184h","article-title":"Identification, design and biological evaluation of\nheterocyclic quinolones targeting Plasmodium falciparum Type II NADH:quinone\noxidoreductase (PfNDH2)","volume":"55","author":"Leung","year":"2012","journal-title":"J. Med. Chem."},{"key":"2026090218203094600_cit43","doi-asserted-by":"publisher","first-page":"8298","DOI":"10.1073\/pnas.1205651109","article-title":"Generation of quinolone\nantimalarials targeting the Plasmodium falciparum mitochondrial respiratory\nchain for the treatment and prophylaxis of malaria","volume":"109","author":"Biagini","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090218203094600_cit44","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1021\/jm3001482","article-title":"Identification of novel antimalarial chemotypes via\nchemoinformatic compound selection methods for a high-throughput screening\nprogram against the novel malarial target, PfNDH2: Increasing hit\nrate via virtual screening methods","volume":"55","author":"Sharma","year":"2012","journal-title":"J. Med.\nChem."},{"key":"2026090218203094600_cit45","doi-asserted-by":"publisher","first-page":"177ra37","DOI":"10.1126\/scitranslmed.3005029","article-title":"Quinolone-3-diarylethers:\na new class of antimalarial drug","volume":"5","author":"Nilsen","year":"2013","journal-title":"Sci. Transl.\nMed."},{"key":"2026090218203094600_cit46","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1021\/jm500147k","article-title":"Discovery, synthesis, and optimization\nof antimalarial 4(1H)-quinolone-3-diarylethers","volume":"57","author":"Nilsen","year":"2014","journal-title":"J. Med. Chem."},{"key":"2026090218203094600_cit47","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2174\/1568026614666140808124638","article-title":"4(1H)-Pyridone and 4(1H)-quinolone\nderivatives as antimalarials with erythrocytic, exoerythrocytic, and\ntransmission blocking activities","volume":"14","author":"Monastyrskyi","year":"2014","journal-title":"Curr. Top.\nMed. Chem."},{"key":"2026090218203094600_cit48","unstructured":"Monastyrskyi, A.; LaCrue, A. N.; Mutka, T. S.; Sakhno, Y.; Kyle, D. E.; Manetsch, R.\n          Synthesis and evaluation of 4(1H)-quinolone prodrugs targeting multi-drug resistance P. falciparum malaria.  245th\nACS National Meeting New Orleans, LA, April 7-11, 2013; American Chemical Society: Washington,\nDC, 2013; MEDI-388."},{"key":"2026090218203094600_cit49","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.4155\/fmc.12.177","article-title":"Exploration of 4(1H)-pyridones as a novel family of\npotent antimalarial inhibitors of the plasmodial cytochrome bc1","volume":"4","author":"Bueno","year":"2012","journal-title":"Future Med. Chem."},{"key":"2026090218203094600_cit50","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1039\/C5MD00062A","article-title":"2-Pyridylquinolone antimalarials\nwith improved antimalarial activity and physicochemical properties","volume":"6","author":"Charoensutthivarakul","year":"2015","journal-title":"MedChemComm"},{"key":"2026090218203094600_cit51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/BF00499836","article-title":"Differential electrophysiological\nand behavioral responses to optically active derivatives of phencyclidine","volume":"315","author":"Marwaha","year":"1981","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"2026090218203094600_cit52","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.1021\/jo049658b","article-title":"Copper\u2013diamine-catalyzed N-arylation of pyrroles,\npyrazoles, indazoles, imidazoles, and triazoles","volume":"69","author":"Antilla","year":"2004","journal-title":"J. Org. Chem."},{"key":"2026090218203094600_cit53","doi-asserted-by":"publisher","first-page":"11684","DOI":"10.1021\/ja027433h","article-title":"The copper-catalyzed N-arylation\nof indoles","volume":"124","author":"Antilla","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"2026090218203094600_cit54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1021\/jm1010995","article-title":"Aurora\nkinase inhibitors based on the imidazo[1,2-a]pyrazine core: Fluorine\nand deuterium incorporation improve oral absorption and exposure","volume":"54","author":"Kerekes","year":"2011","journal-title":"J. Med. Chem."},{"key":"2026090218203094600_cit55","doi-asserted-by":"publisher","first-page":"14844","DOI":"10.1021\/ja028865v","article-title":"Copper-catalyzed halogen exchange in aryl halides:\nAn aromatic Finkelstein reaction","volume":"124","author":"Klapars","year":"2002","journal-title":"J. Am. Chem.\nSoc."},{"key":"2026090218203094600_cit56","unstructured":"Taniguchi, T.; Kawada, A.; Kondo, M.; Quinn, J. F.; Kunitomo, J.; Yoshikawa, M.; Fushimi, M.\n          Preparation of pyridazinone\ncompounds as phosphodiesterase 10A inhibitors for preventing and treating\nschizophrenia. US20100197651A1, 2010."},{"key":"2026090218203094600_cit57","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1128\/AAC.01183-15","article-title":"ELQ-300 prodrugs for enhanced delivery\nand single-dose cure of Malaria","volume":"59","author":"Miley","year":"2015","journal-title":"Antimicrob.\nAgents Chemother."},{"key":"2026090218203094600_cit58","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/iai.64.6.2062-2069.1996","article-title":"An in vitro model for sequential study of shiftdown\nof Mycobacterium tuberculosis through\ntwo stages of nonreplicating persistence","volume":"64","author":"Wayne","year":"1996","journal-title":"Infect.\nImmun."},{"key":"2026090218203094600_cit59","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular\ngrowth and survival: application to proliferation and cytotoxicity\nassays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"2026090218203094600_cit60","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/toxsci\/kfm052","article-title":"Circumventing the Crabtree effect:\nreplacing media glucose with galactose increases susceptibility of\nHepG2 cells to mitochondrial toxicants","volume":"97","author":"Marroquin","year":"2007","journal-title":"Toxicol.\nSci."},{"key":"2026090218203094600_cit61","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1128\/AAC.00623-10","article-title":"Raltegravir is a substrate\nfor SLC22A6: a putative mechanism for the interaction between raltegravir\nand tenofovir","volume":"55","author":"Moss","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090218203094600_cit62","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1080\/00498250802050880","article-title":"Validation and application of Caco-2 assays for the\nin vitro evaluation of development candidate drugs as substrates or\ninhibitors of P-glycoprotein to support regulatory submissions","volume":"38","author":"Elsby","year":"2008","journal-title":"Xenobiotica"},{"key":"2026090218203094600_cit63","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with\nPmetrics, a nonparametric and parametric pharmacometric modeling and\nsimulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther. Drug Monit."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6b01718","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/60\/9\/3703\/67033780\/acs.jmedchem.6b01718.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/60\/9\/3703\/67033780\/acs.jmedchem.6b01718.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:20:57Z","timestamp":1788387657000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/60\/9\/3703\/696832\/Rational-Design-Synthesis-and-Biological"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":63,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,3,17]]},"published-print":{"date-parts":[[2017,5,11]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01718","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,17]]}}}